Image

PROTAC Drug Veppanu

PROTAC Drug Veppanu

Overview :

FDA approved vepdegestrant (Veppanu) on 1 May 2026 for advanced breast cancer with ESR1 mutations. The oral drug doubles progression-free survival (5.0 vs 2.1 months) compared to standard therapy. It's the first PROTAC drug approved globally. Arvinas and Pfizer developed it.

A New Way to Fight Cancer

Think of traditional cancer drugs as locks.

They block proteins. Stop them from working. But the proteins still exist.

PROTAC drugs take a different approach. They're like demolition crews. They don't just block the protein. They destroy it completely.

Veppanu (vepdegestrant) is the first FDA-approved PROTAC drug. That's a big deal.

What Does Veppanu Treat?

Estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer. Specifically in patients with ESR1 mutations.

That's a mouthful. Let's break it down:

  • Estrogen receptor-positive = cancer grows in response to estrogen

  • HER2-negative = doesn't have the HER2 protein

  • ESR1-mutated = has a specific genetic change in the estrogen receptor gene

These patients often develop resistance to standard endocrine therapy. Veppanu gives them a new option.

How Effective Is It?

The Phase 3 VERITAC-2 trial (NCT05654623) showed impressive results:

In ESR1-mutated patients:

  • Median progression-free survival: 5.0 months vs 2.1 months for fulvestrant (standard therapy)

  • Objective response rate: 19% vs 4%

That's more than double the time before the cancer progresses.

What's the Dose?

200 mg taken orally once daily with food. Continue until disease progression or unacceptable toxicity.

Simple. A pill. Not an infusion.

The Companion Diagnostic

FDA also approved Guardant360 CDx as a companion diagnostic on 1 May 2026.

Think of it as a screening tool. It identifies patients with ESR1 mutations. Only those patients should receive Veppanu.

Companion diagnostics are laboratory tests that help select patients for specific treatments.

Safety Warnings

Two key warnings:

  • QTc interval prolongation (affects heart rhythm)

  • Embryo-fetal toxicity (harm to developing fetus)

Doctors will monitor patients closely.

Why PROTAC Matters

PROTAC stands for Proteolysis Targeting Chimera.

Think of it as a smart demolition system. It tags harmful proteins for destruction. The cell's natural disposal system (proteasome) then destroys them.

This approach could revolutionize drug discovery. Many diseases involve problematic proteins. PROTACs could target them all.

Approval Speed

FDA approved Veppanu one month ahead of its goal date. Used the Assessment Aid process. Fast track for promising drugs.

Indian Context

India's pharmaceutical industry watches these developments closely. Generic versions may follow. Startups in biotech could explore PROTAC technology.

Agri-food exports? Not directly related. But biotechnology advances often cross sectors. Drug discovery tools sometimes apply to agricultural innovation.


Exam-Focused Points:

  1. Vepdegestrant (Veppanu)  – first FDA-approved PROTAC (Proteolysis Targeting Chimera) drug.

  2. Approved on 1 May 2026  for ESR1-mutated advanced/metastatic breast cancer.

  3. Developed by  Arvinas Operations, Inc. and Pfizer Inc.

  4. Dose:  200 mg orally once daily with food.

  5. VERITAC-2 trial  showed 5.0 months progression-free survival vs 2.1 months for fulvestrant.

  6. Guardant360 CDx  approved as companion diagnostic for ESR1 mutation detection.

  7. Warnings:  QTc interval prolongation and embryo-fetal toxicity.


FAQs:

Q1: What is Veppanu?
Vepdegestrant, the first FDA-approved PROTAC drug for ESR1-mutated breast cancer.

Q2: What does PROTAC stand for?
Proteolysis Targeting Chimera – a protein-degrading medicine.

Q3: How effective is Veppanu?
In trials, it doubled progression-free survival (5.0 months vs 2.1 months) and showed 19% response rate vs 4% for standard therapy.

Q4: Who should take Veppanu?
Adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer who progressed on endocrine therapy.

Q5: What companion diagnostic was approved?
Guardant360 CDx for identifying ESR1 mutations.

Month: 

Category: 

1